Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have inflammation in the cerebellum, the part of the brain that helps control movement ...

Multiple sclerosis (MS) affects an estimated 2.3 million people worldwide. Approximately 80% of people with MS have ...

Multiple sclerosis (MS) includes both peripheral and central nervous system (CNS) inflammation, and an anti-inflammatory ...

Tiziana (TLSA) is showing groundbreaking advancements in Alzheimer's & MS treatments with foralumab. Key trials & market ...

Shares of Tiziana Life Sciences climbed after the company said it has expanded a Phase 2 clinical trial that is underway of its treatment for multiple sclerosis, an autoimmune condition that affects ...

Presenter: Ivor Elrifi, CEO of Tiziana Life Sciences Presentation Title: Treatment of Neuroinflammation with Intranasal Foralumab Location : Boston Convention & Exhibition Center, Boston, MA ...

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click ...

In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...

multiple sclerosis (MS). Patients with secondary progressive MS (SPMS) experience continuous worsening of symptoms independent of the occurrence of relapses. Possible risk factors associated with the ...

We aimed to study environmental risk factors and their interactions with human leucocyte antigen DRB1*15:01 with regards to relapsing-onset and progressive-onset MS. Methods We used two Swedish ...

According to Dr Asif Ahmed, an NHS GP , if you have pain, fatigue or visual problems, which worsen in hot weather, it could be a sign of the disease.

and Late MS – Secondary Progressive MS (SPMS), which affects the majority of patients, usually after 10 to 15 years after diagnosis. SPMS results from progressive neuronal degeneration that causes ...